Given the pivotal role of HMGN1 in peri-tumor infiltration of lymphocytes, combining HMGN1 targeting with immunotherapy might achieve better therapeutic outcomes for lung adenocarcinoma. The gene discussed is HMGN1; the disease is lung adenocarcinoma.